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Abstract
We aimed to evaluate the outcome of different treatment modalities for extremity venous thrombosis (VT) in neonates and
infants, highlighting the current debate on their best tool of management. This retrospective study took place over a 9-year period
from January 2009 to December 2017. All treated patients were referred to the vascular and pediatric surgery departments from
the neonatal intensive care unit. All patients underwent a thorough history-taking as well as general clinical and local examination
of the affected limb. Patients were divided into 2 groups: group I included those who underwent a conservative treated with the
sole administration of unfractionated heparin (UFH), whereas group II included those who were treated with UFH plus warfarin.
Sixty-three patients were included in this study. They were 36 males and 27 females. Their age ranged from 3 to 302 days. Forty-
one (65%) patients had VT in the upper limb, whereas the remaining 22 (35%) had lower extremity VT. The success rate of the
nonsurgical treatment was accomplished in 81% of patients. The remaining 19% underwent limb severing, due to established
gangrene. The Kaplan-Meier survival method revealed a highly significant increase in both mean and median survival times in those
groups treated with heparin and warfarin compared to heparin-only group (P < .001). Nonoperative treatment with antic-
oagulation or observation (ie, wait-and-see policy) alone may be an easily applicable, effective, and a safe modality for management
of VT in neonates and infants, especially in developing countries with poor or highly challenged resource settings.
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Introduction
Neonatal and infantile venous thrombosis (VT) although being
rare has dramatically increased during the last decade by over
70%.1 This pathology poses a major challenge to neonatolo-
gists, pediatricians, and surgeons with an increased morbidity,
mortality and health-care costs.2 The increased incidence may
be attributed to the more aggressive care of neonates and
infants with serious and life-threatening disorders.1-3 Pro-
longed use of intravenous (IV) catheters may be indicated by
the occurrence of superficial thrombophlebitis and, less often,
deep VT (DVT). Various indirect factors such as prolonged
sepsis, trauma, and congenital heart diseases may trigger spon-
taneous thrombosis in the pediatric population.4,5 In critically
ill neonates and infants, central venous catheters (CVCs) are
commonly used for parenteral nutrition/giving medication.
These catheters are usually inserted in central or peripheral
veins. However, the most frequently encountered complica-
tions associated with CVC insertion is the development of
VT. The incidence of CVC-related thrombosis in neonates
and infants depends on the type of the catheter used, the used
diagnostic tests, and the index of suspicion for development of
thrombosis.6,7 Development of spontaneous/catheter-related
VT may be associated with prothrombotic genetic factors
compared to the general population.8,9 Consequently, venous
thromboembolism (VTE), despite being rare, may lead to
gangrene of the extremities in those neonates and infants.
Conservative management of this pathology is the best option
for treating most of the cases with an ongoing debate regard-
ing which treatment modality is the best.10,11 The aim of this
work was to evaluate the outcome of different treatment mod-
alities for treatment of post-injection/infusion peripheral
venous gangrene in neonates and infants, highlighting the
current debate.
Methods
This 9-year retrospective study was performed from January
2009 until December 2017, after being approved by our insti-
tutes’ researcher board ethical committees. Infants and neo-
nates were considered for enrollment if they were referred
from the neonatal intensive care unit for having manifestations
of upper or lower extremity threatening gangrene post-IV
injection/infusion. Those patients’ files were thoroughly
reviewed. Patients were classified into 2 groups; the first group
(GI) included those who underwent the administration of
unfractionated heparin (UFH) alone, whereas the second group
(GII) included those who had the same regimen of UFH, plus
the addition of warfarin (vitamin K antagonists). Clinically,
neonates and infants were considered having extremity VT and
consequently gangrene if they were presented with an extre-
mity swelling, limb pain, cyanotic/hyperemic/tenderness of the
affected arm or leg, or with a fixed color change. Also consid-
ered as VT, were the presence of subcutaneous collateral veins,
(provided that there is a history of either IV injection/infusion
of the affected limb), CVC dysfunction, as well as unexplained
thrombocytopenia, hemodynamic disturbance, and arrhyth-
mias.12-14 Excluded from this study were those patients with
arterial thrombosis, cerebral sinus VT, renal vein thrombosis,
hemolytic disorders, and those with preexisting/known
prothrombotic risk factors (diagnosed by laboratory tests).
Diagnostic imaging modalities included color Doppler ultraso-
nography, contrast venography, and computerized tomography
scanning/magnetic resonance venography as described in the
literature.15 Furthermore, local treatment to the affected limb
was adopted by removal of the IV line, cold fomentations, local
antiseptic, and limb elevation. Systemic antibiotics after gain-
ing blood culture were carried out. Following exclusion of
intraventricular bleeding, patients are allocated to systemic
anticoagulation therapy. Additionally, -pretreatment labora-
tory testing was conducted, including complete blood count-
ing in addition to platelet count, activated partial
thromboplastin time (aPTT), prothrombin time as well as the
international normalized ratio (INR), alanine aminotransfer-
ase, aspartate aminotransferase, bilirubin total and direct as
well as creatinine levels. As previously described,16,17 all
patients were conservatively treated with anticoagulants,
namely UFH with a dosage of 75 to 100 units/kg over
10 minutes duration. Moreover and according to the recom-
mendations of the American College of Clinical Pharmacy
guidelines for heparin administration with prior warfarin
intake, the required time to reach a therapeutic level ranged
between 3 to 5 days due to the procoagulant transient effect.18-
20 It was avoided in those children who had a significant risk
of bleeding. According to the CHEST guidelines, the initial
infusion stated with a dosage of 28 units/kg per hour, with
infants (aged 2 months up to < 1 year corrected for gestational
age); yet, we considered the individual risk factors when
choosing initial dose.21-23 The adjustment of heparin mainte-
nance dose was determined to maintain aPTT between 55 and
85 seconds. It was usually assessed within 4 to 6 hours of the
loading heparin dosage and 4 hours post any change in the
infusion rate. It was measured daily once the needed thera-
peutic levels were achieved.22 Furthermore, we adopted the
use of an initial warfarin dosage of 0.33 mg/kg aiming to
reach a therapeutic INR level of 2.5 (ranging 2.0-3.0),
according to the infantile INR nomogram24,25 (Table 1).
Heparin-induced major bleeding was treated by the transient
termination of IV heparin infusion, in addition to the imme-
diate administration of protamine sulfate and blood transfu-
sion. The dose of protamine sulfate was determined according
to the previously 2 hours of heparin administration.21
Table 1. Dose of Anticoagulants.
Factor
GI Heparin
Only
(n ¼ 46)
GII Heparin þ
Warfarin (n ¼ 17)
Anticoagulant
dose
Initial 75-100 U/kg 75-100 U/kg þ 0.33mg/kg
Maintenance 28 U/kg/h 28 U/kg/h þ 0.33mg/kg
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Statistical Analysis
Data were statistically analyzed using the Statistical Package
for the Social Science (SPSS) version 23, IBM Corporation,
Armonk, New York. Continuously distributed variables were
summarized by the mean and standard deviation (SD) or
median and range. In addition, odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated. Finally, the
Kaplan-Meier survival analysis was used to graphically
describe amputation-free survival and a P-value of < .05 was
statistically significant.
Results
Sixty-three patients were included in this study. They were 36
males and 27 females with the male to female ratio of 1.3:1.
Their age ranged from 3 up to 302 days with a mean of (72.10
+ 61.60). Most patients were premature 79% (n ¼ 50), with a
gestational age range from 32 to 34 weeks (mean ¼ 33 + 8;
Table 2). Forty-one (65%) patients had VT in the upper limb
(Figure 1), whereas the remaining 22 (35%) had lower limb VT
(Figure 2). Out of those 41 patients with upper limb VT, 4
(6.5%) patients had only 1 finger gangrene. Three (5%) patients
had gangrene affecting more than 1 finger, and 1 patient (1.5%)
had gangrene of the whole hand. On the other hand, 4 (6%)
patients with lower limb VT developed gangrene in 1 toe 3%
(n¼ 2), multiple toes in 1.5% (n¼ 1), and whole foot gangrene
in 1.5% (n ¼ 1; Table 2). Seventeen (77.3%) patients under-
went central venous catheterization inserted into the femoral
vein whereas the remaining 5 (22.7) patients had a peripheral
venous catheter. The overall success rate of the nonsurgical
treatment adopted on all patients was 81% (n ¼ 51). The
remaining 19% (n ¼ 12) patients underwent amputation due
to an established gangrene. However, in GI, 46 patients who
underwent treatment with UFH alone, 35 of them showed the
success of the treatment, whereas in the remaining 11 patients
the treatment was not successful necessitating finger, toe, or
even limb amputation in. Alternatively, in GII, 16 patients
showed a successful response to the combination of UFH and
warfarin therapy with only 1 patient who underwent little toe
amputation due to the failure of treatment (Table 3 and
Figure 3). The average time of conservative treatment showed
a range of 7 to 22 days (mean ¼ 15.1 + 1.6). The total mor-
tality rate was 3 (5%) out of the total 63 patients. Postopera-
tively, 2 patients died due to severe sepsis whereas the
remaining one expired before surgery due to severe compli-
cated multiple congenital anomalies.
Major bleeding events because of UFH administration were
encountered among 2 (3%) patients in GI and in 1 (1.5%)
patient in GII. Yet, warfarin-induced major bleeding was not
Table 2. Patient’s Demographics and Lesion Characteristics.
Patient’s age (n ¼ 63)
Mean + SD,
61.58 + 72.10
Range in (days):
3-302
Patient’s gestational
age (n ¼ 24)
Mean + SD,
33 + 8
Range in
(weeks): 32-34
Gender Male 36 (57.1%)
Female 27 (42.9%)
Upper limb gangrene:
n ¼ 8 (12.5%)
Single finger gangrene 4 (6.5%) 12 (19%)
Multiple finger gangrene 3 (5%)
Whole hand gangrene 1 (1.5%)
Lower limb gangrene:
n ¼ 4 (6.5%)
Single toe gangrene 2 (3%)
Multiple toes gangrene 1 (1.5%)
Whole foot gangrene 1 (1.5%)
Abbreviation: SD, standard deviation
Figure 1. Gangrene of the right hand and right forearm.
Figure 2. Gangrene of the left foot and left leg.
Table 3. Results of Treatment of Impending Gangrene.
Factor N % Total
Nonsurgical treatment 51 81 63 (100%)
Limb severing 12 19
Group I—heparin alone 46 73 63 (100%)
Group II—heparin and warfarin 17 27
Patients improvement after successful treatment with
anticoagulation
51/63 (81%)
Failed treatment ended by upper limb
amputation
8 12.5 12/63 (19%)
Failed treatment ended by lower limb
amputation
4 6.5
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encountered in any of our patients. Moreover, the absolute risk
for the development of gangrene because of VT combining
warfarin with heparin was about 6% compared to using heparin
alone at 24%. Moreover, the cross-relation between the meth-
ods of treatment and the incidence of amputation revealed that
11 cases out of 46 treated with heparin had an amputation. On
the other hand, only 1 patient out of those 17 treated with
heparin and warfarin developed gangrene and underwent
amputation. The OR was 4.065 and the CI was 0.56 to 29.15
(Table 4). This means that patients treated with UFH group
(GI) were more vulnerable to amputation, approximately 5
times compared to those heparin and warfarin-treated group
(GII). The mean and median survival time of the 2 groups with
different treatment options are shown in (Table 5). Moreover,
there was a highly significant increase in both the mean and the
median survival times in the heparin and warfarin-treated
group compared to the heparin-only group (P < .001), as
depicted in (Figure. 4).
Discussion
The highest risk of developing VT and consequently gangrene
does exist among neonates and infants with critical illness. This
may lead to changes in hemostatic balance toward thrombo-
sis.26-28 Many factors may have contributed to the increased
incidence of this condition up to almost 3-folds in the last 2
decades. The accused factors are mainly sepsis, liver dysfunc-
tion, peripheral and central venous lines, fluid fluctuations, and
systemic inflammation.1,29 Central venous catheter is one of
the most common clinical factors that may be responsible for
the development of VT and gangrene.26-28 Due to both
increased plasma levels of plasminogen activator inhibitor and
decreased plasma activity of plasminogen, the activity of the
fibrinolytic system in the newborn is reduced compared to
adults and older children. This fact may explain the high rate
of VT associated with the insertion of intravascular devices in
the newborns.21
Treatment of a newborn with VT is usually difficult with the
use of antithrombotic therapy. This may be due to the altered
physiology and metabolism of the anticoagulants.30,31 The cur-
rent study reported 4 (6.5%) cases who underwent VT and
consequently gangrene of the lower limb induced by CVCs.
These data are contradicting with a 30% incidence of CVC-
associated VT in a previously published report.27 Moreover,
venous thromboses are more likely pronounced in premature
infants.32 We also reported VT in 38.1% premature infants.
This is comparable to other literature data, whereas preterm
neonates accounted for 34% of the thrombosis.26 Most of our
patients were in the neonatal period (n ¼ 55) 87%, coinciding
with previously published reports that showed an incidence of
neonatal thrombosis to be 2.4/1000 and 5.1/100.000, respec-
tively.13,30 It may be due to a higher hematocrit as well as the
greater liability of the hemostatic system because of a general
decrease in levels of coagulation factors and their inhibitors in
neonates.31,32 Neonatal extremity VT and consequently gang-
rene is usually treated conservatively aiming to prevent the
occurrence of infection at the affected part, allowing the gang-
renous area to declare spontaneously in order to optimize any
future reconstruction.33
The anticoagulant most commonly used in the treatment of
neonatal VTE is UFH, although LMWH can also be used. The
advantages of UFH include the potentially easier reversibility
with protamine sulfate.34 However, bleeding complication is
the main risk-associated with heparin administration. The inci-
dence of bleeding complication following anticoagulant
administration in our series was reported in 3% and 1.5% in
GI and GII, respectively. These results coincide and nearly
similar to the previously published reports of 2% incidence
of major bleeding using UFH,28 although it contradicts to other
literature data reporting an incidence that reached 24%.29
The recommendations for treatment of adult VTE cannot
apply to the management of neonatal and infantile VTE, as
their vascular system, the hemostatic system, and comorbid-
ities create a balance of hemorrhage and thrombosis. The
severity of the thrombosis, the possibility of limb impairment,
the presence of comorbidities, and the risk of bleeding all
influence the decision to treat or to observe. Randomized
trials evaluating type and duration of treatment are lacking
in the neonatal population, and treatment decisions are largely
based on consensus evidence-based guidelines. The anticoa-
gulant therapy reduces the risk of thrombus extension and
subsequently pulmonary embolism, while allowing the natu-
ral fibrinolytic system to gradually reduce the clot size.35
Although controversy exists in the literature, as regard the
best tool for conservatively treating VT and consequently
gangrene, we reported 51 (81%) patients out of 63 patients
with a good response to UFH despite not using LMWH
because of the financial limitations in our settings. Neverthe-
less, previously published data from highly developed settings
expressing both the Canadian and German experience sug-
gested the use of thrombolysis and anticoagulation in the form
of UFH and LMWH as the primary tool for treating this con-
dition. Yet, it is difficult to verify which treatment modality is
superior to the other.10,13,30
Figure 3. Patients treated conservatively and those undergoing
amputation.
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In those 2 registries, the most frequently used drug was
heparin as the anticoagulant of choice. Other Canadian
research did use the LMWH and found out that it might have
the advantages over the standard UFH. This may explain that
neonates and infants might require LMWH as well as UFH.36,37
Furthermore, monitoring of the therapeutic effect of LMWH
requires the determination of anti-Xa, which is practically
unfeasible in our settings.
Conclusion
Catheter-related VT—whether centrally or peripherally
located—was frequently encountered in our series, despite
their little number in the literature. This may be due to the
presence of infection/inadequate nursing care owing to lack of
training in proper insertion and hygienic care of the venous
catheters in neonates and infants. Therefore, it is strongly
recommended to adopt more aggressive programs on teaching
nurses and paramedics indulged in the neonatal care on how to
properly insert and hygienically care of venous catheters.
Additionally, we highly advocate the initial aggressive ther-
apy using heparin with early bridging with warfarin. This
regimen is feasible, reliable, effective, and may be safe mod-
ality for management of neonatal and infantile extremity VT
having good outcome results with a lower incidence of ampu-
tation, especially in developing countries with poor or highly
limited-resource settings. The study is limited by the varia-
bility of vascular care policies and procedures among the
different institutions in the study. Another issue is the lack
of information on infants and children hospital course, and on
associated diagnosis of familial or genetic thrombotic disease.
These limitations may be solved by adopting a future prospec-
tive research on the topic.
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Table 4. Cross Tabulation Between Treatment and Amputation in the Studied Groups.
Operative and Nonoperative Procedures
TotalNo amputation Amputation
Treatment Heparin Count 35 11 46
% within treatment (AR) 76.1% 23.9% 100%
Heparin þ warfarin Count 16 1 17
% within treatment (AR) 94.1% 5.9% 100%
Total Count 51 12 63
% within treatment 81% 19% 100%
Pearson w2 ¼ 2.617, P ¼ .106
Odds ratio (heparin/heparin þ warfarin) ¼ 0.199; CI ¼ 0.024-1.67
Odds ratio (heparin þ warfarin/heparin) ¼ 4.065; CI ¼ 0.56-29.15
Abbreviations: AR, absolute risk; CI, confidence interval.
Table 5. Mean and Median Survival Times in the Studied Groups
Group
Mean Median
Estimate SE Estimate SE
Heparin only (group I) 8.000 0.382 8.000 0.672
Heparin and warfarin (group II) 31.938 9.561 10.000 2.000
w2 ¼ 10.421, df ¼ 1, P < .001
Abbreviations: df, degree of freedom; SE, standard error.
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